Low Testosterone Spikes Prostate Cancer Death Risk by 30%.

In 2025, S. Fattahi and a team studied men with prostate cancer in a randomized cohort, followed over time. They analyzed testosterone levels at diagnosis, adjusting for age, cancer stage, and treatments like hormone therapy, to check links with cancer severity and death rates. Prostate-specific antigen (PSA) is a protein made by the prostate gland, measured in blood tests to screen for prostate cancer; high levels can signal cancer, but low levels may hide it.

Men with low testosterone had higher-stage cancers and faced increased prostate cancer death risk by 20-30% and all-cause death by 15-25% compared to those with normal levels. Low testosterone hides PSA rises, delaying detection—33% of standard biopsies miss significant tumors. This risk is higher in otherwise healthy men, where under-detection, not other illnesses, drives worse outcomes.

Ask your doctor about MRI screening alongside PSA tests if you have low testosterone to catch prostate cancer early.